Investors Buy Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) saw unusually large options trading activity on Friday. Stock investors purchased 26,656 call options on the company. This represents an increase of 44% compared to the typical daily volume of 18,485 call options.

ImmunityBio Price Performance

Shares of IBRX stock traded down $0.50 during trading hours on Friday, reaching $9.50. 10,962,955 shares of the stock were exchanged, compared to its average volume of 20,563,473. The business’s fifty day moving average is $8.54 and its two-hundred day moving average is $7.96. The firm has a market capitalization of $10.07 billion, a P/E ratio of -9.82 and a beta of 0.02. ImmunityBio has a 12-month low of $1.95 and a 12-month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. As a group, equities research analysts predict that ImmunityBio will post -0.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on IBRX shares. Jefferies Financial Group boosted their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research note on Thursday. Finally, Piper Sandler reissued an “overweight” rating and set a $16.00 target price on shares of ImmunityBio in a research note on Wednesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Insider Transactions at ImmunityBio

In other news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the sale, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director directly owned 2,777,788 shares of the company’s stock, valued at approximately $29,861,221. The trade was a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently modified their holdings of the company. Fortress Financial Solutions LLC purchased a new stake in ImmunityBio during the 3rd quarter worth about $105,000. Firethorn Wealth Partners LLC boosted its position in shares of ImmunityBio by 107.9% during the 3rd quarter. Firethorn Wealth Partners LLC now owns 25,475 shares of the company’s stock worth $240,000 after acquiring an additional 13,219 shares in the last quarter. Courier Capital LLC increased its holdings in shares of ImmunityBio by 100.0% in the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company’s stock valued at $1,057,000 after acquiring an additional 56,000 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of ImmunityBio by 262.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after acquiring an additional 2,756 shares during the last quarter. Finally, Collective Family Office LLC raised its position in shares of ImmunityBio by 2.6% during the 3rd quarter. Collective Family Office LLC now owns 161,254 shares of the company’s stock worth $1,522,000 after acquiring an additional 4,054 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA expanded ANKTIVA’s label, in combination with BCG, to include patients with BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors in addition to carcinoma in situ (CIS) disease. The broader indication materially increases the addressable patient population and commercial opportunity. FDA expands ANKTIVA approval
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $15 price target, while raising its FY2027 earnings estimate to $0.10 per share from $0.07. Jefferies also lifted its price target to $14, signaling increased confidence in ImmunityBio’s longer-term earnings potential. Jefferies raises price target
• Neutral Sentiment: The expanded approval arrived ahead of expectations and triggered strong trading interest, but investors are awaiting evidence that the larger label will translate into sustained prescriptions, revenue growth and improved cash-flow performance.
• Negative Sentiment: Retail investors remain cautious despite the FDA decision, with attention turning to the founder’s upcoming trial-related discussion. This hesitation has limited follow-through from the initial regulatory rally. IBRX weekly outlook

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.